Subscribe by Email

About the Blog

The Active Ingredient features expert insights and commentary from leaders of ZS Associates' global pharmaceuticals practice.

Search by Topic

see all

Why Pharma Manufacturers Should Partner With Rare Disease Communities

Posted by ZS Editors on Thu, Jul 06, 2017

Patient communities are a valuable asset within the life sciences industry. In the rare disease space, these groups are a vital resource for families battling disease, and serve as much-needed patient representatives to help spur funding, research and scientific advancement. ZS’s Rachael Pius weighs in on why pharmaceutical companies should view these patient communities as partners in clinical development. 

Read More

Topics: Pharma, rare diseases, clinical trials, patient communities, rachael pius, RWE

Subscribe to The Active Ingredient


Subscribe to receive email notifications whenever new blog posts are published.